ZooMAb antibodies represent an entirely new generation of recombinant monoclonal antibodies.Each ZooMAb antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb antibodies are reliably available and ready to ship when you need them.Learn more about ZooMAb here.
Synonyms: B7 homolog 1; B7-H1; CD274; PDCD1 ligand 1; Programmed cell death 1 ligand 1; Programmed death ligand 1
Storage: 2-8C
Application: Western Blotting Analysis: A 1:100 dilution from a representative lot detected PD-L1/CD274 in mouse placenta tissue lysate.Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected PD-L1/CD274 in MDA-MB-231 and RAW264.7 cell lines.Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected PD-L1/CD274 in human placenta and human lung cancer tissue sections.Affinity Binding Assay: A representative lot of this antibody bound human recombinant PD-L1/CD274 with a KD of 5.5 x 10-8 in an affinity binding assay.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user
Legal Information: ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany